Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Valuation
Trading at 0.2× sales vs its 3.9× historical median P/S.
Fair value ≈ $18.23 · price $1.15 today
Undervalued · 94% below
Loading valuation…
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$CELZ
: A Microcap Biotech Targeting Massive Markets 🧬
Creative Medical Technology Holdings is a regenerative biotech developing stem cell therapies for chronic pain, diabetes, and immune conditions.
🔥 April 28 Breakthrough
✔️ Reported 93% response rate in Ultrasome knee OA study
✔️ Improved pain and mobility, no serious adverse events
✔️ Derived from CELZ-201, enabling a scalable cell free platform
Recent Milestones
✔️ Completed enrollment in Phase 2 ADAPT trial
✔️ Positive interim data with strong response rates
✔️ Second WHO INN milestone, dual programs recognized
Catalysts to Watch
🗓️ Full Phase 2 ADAPT data readout expected in 2026
🗓️ Expansion of Ultrasome into larger clinical studies
🗓️ Potential partnership or licensing discussions
CELZ is expanding into a broader regenerative platform targeting osteoarthritis, chronic pain, and diabetes, a $100B+ opportunity.
Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyCELZ1
Sector Peers: $VXRT $HOOK $ATOS
$CELZ: Bullish Momentum Building After Prolonged Base Formation 📡🧬
Recent price action reflects tight consolidation, with buyers stepping in on dips and volume beginning to expand, suggesting early stage interest returning.
Technical View:
🔹 Prolonged downtrend transitioning into sideways base
🔹 Higher lows forming within consolidation structure
🔹 Compression beneath resistance = potential breakout setup
Key Levels to Watch:
🎯 $2.02 🟰 Key support / reclaim level
🎯 $2.35–$2.51 🟰 Near-term resistance zone
🎯 $2.74 🟰 Breakout confirmation level
🎯 $3.08–$3.34 🟰 Major supply area
It will be interesting to keep on watch management next business update and press releases. Their data results could increase shareholder value significantly
Communicated Disclaimer: http://tinyurl.com/Therealshortsq…
Sector Peers: $VXRT $HOOK $BCDA $CAPR
🧬 $CELZ : A Tiny Biotech Taking a Shot at Huge Markets
Creative Medical Technology Holdings is a regenerative medicine company developing stem cell therapies aimed at treating chronic pain, diabetes, and immune disorders by targeting disease at the source.
Recent Milestones
✔️ Completed patient enrollment in the Phase 2 ADAPT trial for chronic lower back pain
✔️ Reported strong interim data with high response rates and improved function
✔️ Achieved second WHO International Nonproprietary Name milestone (Feb 2026), now with dual programs recognized globally
Catalysts to Watch
🗓️ Full Phase 2 ADAPT data readout expected in 2026
🗓️ Potential follow up trial design or FDA discussions after data release
🗓️ Potential partnership or licensing activity as clinical data matures
With clinical data emerging and multiple programs in play, CELZ is going after $100B+ markets.
Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyCELZ
Sector Peers: $VXRT $HOOK $ATOS $CLRB
$HOOK free money here, absurd undervaluation or am I wrong?
How Is It possible co to liquidate 1.28/1.71 USD when updated cash position/net equity do imply + 2 USD per shareholder even assuming liquidation and dissolution costs, potential indeminifications and tax liabilities?
https://www.otcmarkets.com/file/company/financial-report/547261/content
Take a look at balance sheets, 32 mln USD in net equity as of december 31 + 5 mln USD from GILD + 5 mln USD from NEOTRAIL, should have raised net equity/cash available for distribution.
Certificate of Dissolution should be filed in late april/early May, then stock delisted from OTC because transfer agent will close books.
Am I wrong or market Is underestimating future cash proceeds?
NeoTrail bought asset for 5 mln USD, amount disclosed in the last sec filing, GILEAD completed 10 mln USD deal buying every agreed cent.
I am assuming +- 14 mln fully diluted common shares.
What Is wrong or am I right assuming liquidation North of 2 USD?
$HOOK https://www.otcmarkets.com/file/company/financial-report/507979/content
30 mln in net equity as of September 30 with 12.2 mln shares would be worth 2.45 USD per share in book value.
Then we should Add 7.4 mln USD net by GILEAD for assets purchase plus recents asset sale to Neotrail for undisclosed amount. I assume Dissolution and liquidation costs plus some cash burn should be around 12 mln USD with 25 mln USD left to be liquidated to shareholders when and If certificate of Dissolution filed to Delaware SOS...
25 mln /12.2 shares gives me more than 2 USD per share but according most recent meeting to vote Dissolution liquidation value beetwen 1.28 and 1.72 USD per share, what Is wrong?
I would assume 1.72 at least if not more...
What if bod decides not to file for Dissolution but seeking a merger , there Is a small chance Dissolution cancelled and operations to resume. I find stock very cheap, a Shell with cash and equity without debt or positive equity around 25/30 mln
$BCAB $BCAB The company's strategy for maintaining its listing has never been successful. Fact check!
1. Maintain MVLS -> Failure (Nasdaq Disapproval)
2. BP partnership -> Failure (only inversagen AI deal)
3. bid compliance -> Failure (until 2/2)
4. PPA induces high stock conversion(11/26) -> failure, Yorkville maybe exit at Dec, Jan.
5. Issuance of Super Voting Rights -> Failure (Nasdaq Disapproval)
6. RS Strategy -> Failed twice
7. cash -> burning state
8. equity -> Only numbers are resolved through a joint venture from a company related to the representative(invergagen AI). deposit is unknown or secured)
9. Reverse merger -> ???? maybe f.....
All that remains is liquidation or delisting. However, after liquidation, the cost for liquidation of creditors and executives and employees comes first. There is no shareholder's share. like $HOOK
$HOOK I would expect liquidation to happen at higher range around 1,71 USD given co.completed asset sale to GILEAD and now NEOTRAIL, its a matter of patience. I dont see any downside but only upside, strange pps does not hit 1,28 USD the minimum liquidation value. Holding tight my shares. Do your due diligence before investing your Money. This Is not a financial advice.
